US · ABT
Abbott Laboratories
- Sector
- Healthcare · Medical - Devices
- Headquarters
- North Chicago, IL 60064-6400
- Website
- abbott.com
Price · as of 2025-12-31
$89.46
Market cap 202.45B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $85.58 | -4.34% |
| Intrinsic Value(DCF) | $48.62 | -45.65% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $50.37 | -43.7% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $21.09 | $46.21 | $28.78 | $0.00 | $54.43 |
| 2012 | $27.05 | $43.50 | $4.90 | $0.00 | $40.16 |
| 2013 | $31.41 | $36.52 | $2.49 | $9.72 | $0.00 |
| 2014 | $38.03 | $37.31 | $4.31 | $1.82 | $1.59 |
| 2015 | $33.48 | $36.77 | $4.49 | $8.18 | $26.72 |
| 2016 | $38.88 | $43.36 | $11.18 | $0.00 | $9.73 |
| 2017 | $55.24 | $49.80 | $5.99 | $0.00 | $10.44 |
| 2018 | $67.77 | $55.07 | $29.57 | $0.00 | $25.93 |
| 2019 | $73.46 | $57.19 | $37.90 | $0.00 | $25.73 |
| 2020 | $106.52 | $74.77 | $20.33 | $0.00 | $40.98 |
| 2021 | $105.62 | $90.79 | $172.58 | $0.00 | $125.36 |
| 2022 | $91.42 | $76.63 | $83.18 | $0.00 | $37.45 |
| 2023 | $116.36 | $78.09 | $2.83 | $0.00 | $0.95 |
| 2024 | $134.61 | $101.38 | $4.04 | $19.65 | $96.98 |
| 2025 | $114.12 | $85.58 | $5.99 | $0.00 | $50.37 |
AI valuation
Our deep-learning model estimates Abbott Laboratories's (ABT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $85.58
- Current price
- $89.46
- AI upside
- -4.34%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$48.62
-45.65% upside
Graham-Dodd
—
— upside
Graham Formula
$50.37
-43.7% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ABT | Abbott Laboratories | $89.46 | 202.45B | -4% | -46% | — | -44% | 30.56 | 3.82 | 4.50 | 17.79 | — | 8.83 | 55.51% | 18.16% | 14.72% | 13.07% | 10.95% | 7.76% | 0.29 | 23.60 | 1.58 | 1.02 | 0.57 | -5131.00% | 567.00% | 1644.00% | 3.71% | 0.58 | 13.06% | 2.06% | 63.10% | 3.07% | 25.53 | 27.79 | 4.64 | 5.28 |
| BSX | Boston Scientific Corpora… | $76.85 | 114.04B | -12% | -35% | -82% | -31% | 39.02 | 4.66 | 5.62 | 33.01 | 70.68 | -105.55 | 69.01% | 19.78% | 14.38% | 12.57% | 10.11% | 6.96% | 0.51 | 11.38 | 1.62 | 0.91 | 2.78 | 5520.00% | 1987.00% | 3830.00% | 3.24% | 0.83 | 10.90% | 0.00% | 0.00% | 0.32% | 31.03 | 33.68 | 6.14 | 4.56 |
| GILD | Gilead Sciences, Inc. | $148.95 | 184.8B | -18% | -32% | — | -52% | 21.93 | 8.25 | 6.34 | 18.54 | 1.30 | -69.80 | 86.69% | 40.14% | 28.90% | 40.57% | 28.89% | 14.42% | 1.09 | 11.54 | 1.68 | 1.31 | 1.57 | 168421.00% | 240.00% | -824.00% | 5.07% | 0.85 | 26.61% | 2.14% | 47.00% | 3.17% | 16.98 | 21.22 | 6.81 | 4.40 |
| ISRG | Intuitive Surgical, Inc. | $503.51 | 178.81B | -37% | -41% | -82% | -56% | 61.57 | 9.94 | 17.60 | 47.34 | 272.61 | 10.15 | 66.00% | 29.27% | 28.38% | 16.79% | 20.67% | 14.58% | 0.02 | — | 4.87 | 3.77 | -0.85 | 2259.00% | 2051.00% | 9103.00% | 1.41% | 1.51 | 20.12% | 0.00% | 0.00% | 1.96% | 58.22 | 68.85 | 17.04 | 41.40 |
| MDT | Medtronic plc | $97.66 | 125.38B | — | -51% | — | -81% | 41.30 | 2.92 | 4.98 | 22.00 | — | -18.12 | 65.19% | 14.89% | 11.97% | — | — | — | 0.51 | 4.85 | 2.65 | 1.91 | 3.03 | — | — | — | 3.26% | 0.73 | — | 2.08% | 86.00% | 2.52% | 36.91 | 33.88 | 5.50 | 3.26 |
| MRK | Merck & Co., Inc. | $123.78 | 306.03B | +5% | -27% | -61% | -44% | 16.68 | 5.79 | 4.68 | 13.42 | 208.16 | 70.05 | 81.50% | 41.19% | 28.08% | 36.91% | 29.12% | 17.40% | 0.96 | — | 1.54 | 0.96 | 1.42 | 801.00% | 131.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | 12.71 | — | 5.24 | 5.12 |
| NVO | Novo Nordisk A/S | $37.45 | 166.46B | +59% | +7% | — | -3% | 10.46 | 5.52 | 3.60 | 8.17 | 591.70 | 16.74 | 80.34% | 43.69% | 33.14% | 60.70% | 39.34% | 20.31% | 0.67 | 19.92 | 0.80 | 0.48 | 0.73 | 177.00% | 234.00% | -5838.00% | 2.71% | 0.55 | 11.19% | 4.65% | 48.60% | 4.77% | 9.05 | 40.54 | 3.95 | 3.59 |
| NVS | Novartis AG | $168.62 | 325.95B | -29% | -50% | — | -40% | 23.02 | 7.01 | 5.90 | 15.18 | 102.37 | -36.57 | 75.02% | 31.15% | 25.64% | 31.17% | 21.84% | 12.91% | 0.80 | 14.38 | 1.12 | 0.83 | 1.11 | 2249.00% | 597.00% | 2811.00% | 5.47% | 0.71 | 26.49% | 2.43% | 55.90% | 5.29% | 20.44 | 19.73 | 6.37 | 4.35 |
| SYK | Stryker Corporation | $387.46 | 148.28B | -24% | -56% | — | -59% | 45.57 | 6.60 | 5.89 | 25.13 | 552.53 | -57.96 | 63.96% | 19.47% | 12.92% | 15.08% | 11.08% | 7.15% | 0.66 | 8.05 | 1.89 | 1.04 | 1.72 | 825.00% | 1116.00% | 2283.00% | 2.90% | 0.65 | 13.50% | 0.87% | 39.60% | 0.87% | 32.46 | 37.05 | 6.32 | 4.53 |
| TMO | Thermo Fisher Scientific … | $521.11 | 195.79B | -36% | -60% | -86% | -59% | 28.45 | 3.58 | 4.29 | 19.23 | 388.69 | -16.23 | 37.66% | 18.20% | 15.12% | 13.05% | 9.40% | 6.47% | 0.74 | 5.71 | 1.89 | 1.25 | 2.58 | 732.00% | 391.00% | -1340.00% | 3.29% | 0.51 | 7.89% | 0.33% | 9.50% | 1.90% | 27.19 | 35.04 | 4.95 | 2.81 |
| UNH | UnitedHealth Group Incorp… | $293.27 | 265.66B | -28% | +144% | -84% | -12% | 20.96 | 2.68 | 0.60 | 13.82 | — | 2.68 | 18.53% | 4.24% | 2.69% | 13.29% | 11.37% | 4.21% | 0.78 | 4.74 | 0.79 | 0.45 | 2.18 | -1470.00% | 1181.00% | -2236.00% | 5.99% | 0.17 | 11.06% | 2.95% | 61.80% | 5.51% | 16.80 | 19.82 | 0.71 | 2.33 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
- CEO
- Robert Ford
- Employees
- 114K
- Beta
- 0.75
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($48.62 ÷ $89.46) − 1 = -45.65% (DCF, example).